The in vivo tumor growth analysis and ex vivo tumor size measurement revealed that anti-sMCAM mAb treatment decreased DLD1 and LoVo tumor growth as compared to IgG treatments similar to an anti-angiogenic drug (i.e., bevacizumab), which targets human VEGF-A (Figure 4B,C). Here, VEGFA is linked to neoplasm.